Technavio, a tech-focused market research firm, has published a new report on the global age-related macular degeneration market, which is expected to experience a slow but steady growth rate with a CAGR of more than 7% during the forecast period.
This latest report by Technavio covers the market outlook and growth prospects of the global age-related macular degeneration market for 2016-2020, considering 2015 as the base year. In addition, an overview of the market, key leading countries, vendor landscape, and a detailed analysis of the top vendors operating in this market are covered in the report.
Based on geographical division, Technavio market researchers segment the global age-related macular degeneration market into the following key regions: The Americas, APAC, and ROW.
Geographical segmentation of the global age-related macular degeneration market for 2015 (market share %)
|
Americas |
51.04% |
|
EMEA |
28.16% |
|
APAC |
20.8% |
Source: Technavio
The Americas: largest revenue generating region for age-related macular degeneration
The global age-related macular degeneration market in the Americas was valued at around $3 in 2015 and will grow at a CAGR of more than 6% by 2020. The launch of new biologics and expanded access to medical care due to healthcare reforms will drive market growth in this region. The growing consumption of AMD drugs will boost the demand for these products in the American market during the forecast period. Factors such as improved diagnostic techniques and rising effort towards the prevention of blindness among the aging population will help in the development of the American market.
“The US is witnessing the launch of novel therapies with AMD drugs like Squalamine and Fovista releasing in 2017. Furthermore, the presence of patient assistance programs by governmental and non-governmental organizations in the US will boost the demand for these products during the forecast period. The implementation of the Patient Protection and Affordable Care Act in 2010, is providing affordable health insurance, improving the quality of healthcare, and regulating the health insurance industry in the US,” says Sapna Jha, a lead analyst at Technavio, specializing in research on cardiovascular and metabolic disorders.
Click here to request a free sample of this report
AMD market in EMEA
The global age-related macular degeneration market in EMEA was valued at almost $2 in 2015 and will grow at a CAGR of around 7% by 2020. The availability of therapy options in the treatment of CNV will drive market growth in the region. Countries like the UK, France, Italy, Germany, and Spain, will emerge as the key revenue generators in the EMEA market. The increasing awareness of the benefits of the treatment among physicians and affected individuals will boost the demand for products in the market. Moreover, favorable reimbursement policies in Europe will have a positive impact on the development of the market in this region.
AMD market in APAC
The global age-related macular degeneration market in APAC was valued at over $1 in 2015 and will grow at a CAGR of around 11% by 2020. The increasing treatment rate and the high cost of drugs will make APAC the fastest growing region in the market. Countries like Japan, India, and China will contribute to the highest revenues in the region. The rise in patient population and public awareness about the disease will help in the growth of the market. Unhealthy lifestyles, changing dietary habits, and increased use of electronic equipment like computers, TVs, and video games are affecting the normal eyesight of the population in the region and increasing the risk of AMD among the people. The prevalence of prolonged diseases like diabetes and hypertension is leading to the growth in the APAC market.
The top leading vendors operating in the global age-related macular degeneration market are:
- Bayer HealthCare
- F. Hoffmann-La Roche
- Novartis
- Regeneron Pharmaceuticals
Other prominent vendors in the market include Alcon, Allergan, Avalanche, Bausch+Lomb, Gilead Sciences, Iconic Therapeutics, Lpath, Neurotech Pharmaceuticals, Ohr Pharmaceutical, Opthea, Ophthotech Corporation, PanOptica, Pfizer, Promedior, QLT, Quark, Resolvyx Pharmaceuticals, RXi Pharmaceuticals, Sagent Pharmaceuticals, Santen Pharmaceuticals, and Sanwa Kagaku Kenkyusho.
A more detailed analysis is available in the Technavio report titled, ‘Global Age-Related Macular Degeneration Market 2016-2020’. Technavio also customizes reports by other regions and specific segments upon request.
Other related reports:
- Global Choroidal Neovascularization Market 2016-2020
- Global Diabetic Eye Disease Devices Market 2016-2020
- Global Cataract Devices Market 2016-2020
To read more press releases- click here.
For any assistance or query, please contact our media team at:
media@technavio.com
US: +1 630 333 9501
UK: +44 208 123 1770
https://www.technavio.com/
